Hjem › Crohns sygdom › Georgia
Crohns sygdom kliniske forsøg i Georgia
22 studier for Crohns sygdom søger deltagere på steder i Georgia.
Byer i Georgia
Officiel studietekst (engelsk)
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Morehouse School Of Medicine ( Site 5071), Atlanta
- Gastroenterology Associates of Central Georgia ( Site 5048), Macon
RekruttererFase 3
Alder 16 til 80 · Alle køn · Opdateret 2. okt. 2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gastroenterology Associates of Central Georgia /ID# 280464, Macon
- Gastroenterology Consultants - Roswell /ID# 281235, Roswell
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 2. okt. 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Digestive Healthcare of Georgia, Atlanta
- AGA GA Research LLC, Atlanta
RekruttererFase 4
Alder 18 til 80 · Alle køn · Opdateret 30. sep. 2026 · NCT06581328A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Emory University, Atlanta
- Children's Center for Digestive Health Care, Atlanta
RekruttererFase 3
Alder 2 til 17 · Alle køn · Opdateret 25. sep. 2026 · NCT05923073Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Gastroenterology Associates of Central Georgia /ID# 265547, Macon
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 25. sep. 2026 · NCT06548542A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Morehouse School of Medicine, Atlanta
- Gastroenterology Associates of Central GA, Macon
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07499232A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Emory University, Atlanta
- Children's Center for Digestive Health Care, Atlanta
- Gastroenterolgy Associates of Central GA, Macon
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07196722A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Emory University, Atlanta
- Children's Center for Digestive Healthcare, Atlanta
RekruttererFase 3
Alder 3 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06663332A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- Emory University Hospital, The Emory Clinic, Atlanta
- Atlanta Center For Gastroenterology, P.C., Decatur
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 25. sep. 2026 · NCT06233461An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Atlanta Gastroenterology Associates-Site Number: 8400109, Atlanta
- M3 Wake Research - Atlanta-Site Number: 8400028, Sandy Springs
- EBGS Clinical Research Center, LLC-Site Number: 8400037, Snellville
- og 1 flere
RekruttererFase 3
Alder 16 til 80 · Alle køn · Opdateret 23. sep. 2026 · NCT07184931A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- Atlanta Gastroenterology Specialists, PC, Atlanta
- Atlanta Gastroenterology Associates (Part of United Digestive), Atlanta
RekruttererFase 2
Alder 18 til 85 · Alle køn · Opdateret 22. sep. 2026 · NCT06226883A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
- Atlanta Gastroenterology Associates - Peachtree Dunwoody, Atlanta
RekruttererFase 2
Alder 18 til 80 · Alle køn · Opdateret 22. sep. 2026 · NCT07483073A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Emory University School of Medicine, Atlanta
- Children's Center for Digestive Health Care, LLC, Atlanta
RekruttererFase 3
Alder 2 til 19 · Alle køn · Opdateret 22. sep. 2026 · NCT04844606A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
- Atlanta Gastroenterology Associates - Peachtree Dunwoody, Atlanta
RekruttererFase 2
Alder 18 til 80 · Alle køn · Opdateret 22. sep. 2026 · NCT07483099A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- Gastroenterology Consultants, P.C., Roswell
RekruttererFase 4
Alder 18 til 70 · Alle køn · Opdateret 9. sep. 2026 · NCT06045754A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Atlanta Gastroenterology Specialists, Suwanee
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. aug. 2026 · NCT07577843A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Emory University, Atlanta
- Children's Center for Digestive Health Care, LLC, Atlanta
RekruttererFase 3
Alder 2 til 17 · Alle køn · Opdateret 24. aug. 2026 · NCT05509777Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Emory University, Atlanta
RekruttererFase 4
Alder 6 til 17 · Alle køn · Opdateret 27. maj 2026 · NCT05781152A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Childrens Center For Digestive Healthcare, Atlanta
RekruttererFase 3
Alder 2 og opefter · Alle køn · Opdateret 7. maj 2026 · NCT05442567A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- Childrens Center For Digestive Healthcare, Atlanta
RekruttererFase 3
Alder 2 til 17 · Alle køn · Opdateret 5. maj 2026 · NCT04779320A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
- Investigational Site Number: 8400019, Marietta
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 27. mar. 2026 · NCT06958536A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Atlanta
- Mirador Therapeutics Selected Site, Snellville
RekruttererFase 2
Alder 18 til 80 · Alle køn · Opdateret 12. mar. 2026 · NCT07113522Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.